Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion
- PMID: 16516167
- DOI: 10.1016/j.brainres.2006.01.088
Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion
Abstract
In the present study, we elucidated effect of cilostazol to prevent the occurrence of vacuolation and rarefaction of the white matter in association with apoptosis induced by bilateral occlusion of common carotid arteries in the male Wistar rats. Rats orally received vehicle (DMSO) or 60 mg kg(-1) day(-1) (orally) cilostazol for 3, 7, 14 or 30 days. In the vehicle group, increased vacuolation and rarefactions in the white matter were accompanied by extensive activation of both microglial and astroglial cells with suppression of oligodendrocytes in association with increased TNF-alpha production, caspase-3 immunoreactivity and TUNEL-positive cells in the white matter including optic tract. Post-treatment with cilostazol (60 mg kg(-1) day(-1)) strongly suppressed not only elevated activation of astroglia and microglia but also diminished oligodendrocytes following chronic cerebral hypoperfusion. In conclusion, cilostazol (60 mg kg(-1) day(-1), orally) significantly reduced the apoptotic cell death in association with decreased TNF-alpha production and caspase-3-positive cells in the white matter of rat brains subjected to bilateral occlusion of common carotid arteries, consequently ameliorating vacuoles and rarefaction changes in the white matter.
Similar articles
-
Concurrent administration of cilostazol with donepezil effectively improves cognitive dysfunction with increased neuroprotection after chronic cerebral hypoperfusion in rats.Brain Res. 2007 Dec 14;1185:246-55. doi: 10.1016/j.brainres.2007.09.016. Epub 2007 Sep 20. Brain Res. 2007. PMID: 17936728
-
Chronic cerebral hypoperfusion induces white matter lesions and loss of oligodendroglia with DNA fragmentation in the rat.Acta Neuropathol. 2003 Dec;106(6):527-34. doi: 10.1007/s00401-003-0749-3. Epub 2003 Sep 11. Acta Neuropathol. 2003. PMID: 13680276
-
Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion.Stroke. 2006 Jun;37(6):1539-45. doi: 10.1161/01.STR.0000221783.08037.a9. Epub 2006 Apr 27. Stroke. 2006. PMID: 16645134
-
Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury.CNS Neurosci Ther. 2008 Summer;14(2):143-52. doi: 10.1111/j.1527-3458.2008.00042.x. CNS Neurosci Ther. 2008. PMID: 18482026 Free PMC article. Review.
-
Cilostazol: therapeutic potential against focal cerebral ischemic damage.Curr Pharm Des. 2006;12(5):565-73. doi: 10.2174/138161206775474323. Curr Pharm Des. 2006. PMID: 16472148 Review.
Cited by
-
AT1 receptor blocker candesartan-induced attenuation of brain injury of rats subjected to chronic cerebral hypoperfusion.Neurochem Res. 2007 Aug;32(8):1314-21. doi: 10.1007/s11064-007-9305-1. Epub 2007 Mar 31. Neurochem Res. 2007. PMID: 17401654
-
Efficacy of Cilostazol Administration in Alzheimer's Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study.Neurotherapeutics. 2019 Apr;16(2):394-403. doi: 10.1007/s13311-018-00708-x. Neurotherapeutics. 2019. PMID: 30761509 Free PMC article. Clinical Trial.
-
Influence of Cilostazol on Changes in Cyclin D1 Expression in Cerebral Cortex of Rats with Chronic Cerebral Ischemia.Physiol Res. 2020 Aug 31;69(4):695-699. doi: 10.33549/physiolres.934282. Epub 2020 Jun 25. Physiol Res. 2020. PMID: 32584130 Free PMC article.
-
Cerebral Small Vessel Disease (CSVD) - Lessons From the Animal Models.Front Physiol. 2019 Oct 24;10:1317. doi: 10.3389/fphys.2019.01317. eCollection 2019. Front Physiol. 2019. PMID: 31708793 Free PMC article. Review.
-
Reversal of spatial memory impairment by phosphodiesterase 3 inhibitor cilostazol is associated with reduced neuroinflammation and increased cerebral glucose uptake in aged male mice.Front Pharmacol. 2022 Dec 21;13:1031637. doi: 10.3389/fphar.2022.1031637. eCollection 2022. Front Pharmacol. 2022. PMID: 36618932 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials